Pipeline
Therapies in Development
Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver novel therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest need.
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|---|
| Eptinezumab (anti-CGRP mAb)¹ | Migraine prevention² | Filing | |||||
| Eptinezumab (anti-CGRP mAb)¹ | Cluster headache | 3 | |||||
| Lu AG09222 (anti-PACAP mAb)³ | Migraine prevention² | 2 | |||||
| Lu AG13909 (anti-ACTH mAb)⁴ | Neurohormonal dysfunctions | 1 |
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|---|
| Brexpiprazole⁵ | PTSD⁶ | Filing | |||||
| Lu AF28996 (D1-D2 agonist)⁷ | Parkinson's disease | 1 | |||||
| MAGLi program⁸ | Neurology | 1 | |||||
| Bexicaserin (5HT2C agonist) | Developmental and epileptic encephalopathies | 3 |
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Amlenetug (anti α-synuclein mAb) | Synucleinopathies (MSA) | 3 |
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
More from Lundbeck
Research and Development
R&D of new and improved treatments is at the core of what we do.
Restoring Brain Health
What brain health means to us at Lundbeck.
Understanding Brain Diseases
The journey to brain health starts with understanding the diseases in the brain.